Financial Results (Q2 FY2022) - QoQ comparison

The company has reported a total income of Rs. 5580.47 crore during the period ended September 30, 2021, as compared to Rs. 5569.28 crore during the period ended June 30, 2021.

It has posted a net profit of Rs. 711.36 crore for the period ended September 30, 2021, as against net profit) of Rs. 714.72 crore for the period ended June 30, 2021.

Financial Results (Q2 FY2022) - YoY Comparison

It reported a total income of Rs. 5580.47 crore during the period ended September 30, 2021, as compared to Rs.5091.76 crores during the period ended September 30, 2020.

The company has posted a net profit of Rs.711.36 crores for the period ended September 30, 2021, as against a net profit of Rs.665.43 crores for the period ended September 30, 2020.

Financial Results (Half Year Ended FY2022) - YoY Comparison

It has reported a total income of Rs.11149.75 crores during the six months ended September 30, 2021, as compared to Rs.9503.37 crores during the six months ended September 30, 2020.

The company has posted a net profit of Rs.1426.08 crore for the six months ended September 30, 2021, as against a net profit of Rs.1243.34 crore for the six months ended September 30, 2020.

Commenting on the results, Umang Vohra, MD and Global CEO, Cipla said,  “I am pleased to see the strong momentum in core therapies across our branded markets and sustained cost control leading to 10% revenue growth and 22.2% EBITDA margin for the quarter, offsetting price erosion and normalising covid contribution. In India, we continue to drive strong performance led by sustained volume traction despite a high FY21 base. Our collaboration with Eli Lily for their diabetes products helps us further strengthen our endeavour of creating access to innovative medicines in-line with the One-India strategy. The US business also witnessed healthy run rate driven by core portfolio and desired traction in respiratory franchise across Albuterol and Arformoterol. International markets rebounded in-line with expectations despite continuing geopolitical challenges.’’